Volume 17 Supplement 1

Immunotherapy Bridge 2018 and Melanoma Bridge 2018

Meeting abstracts

Publication charges for this supplement were funded by 3P Solution, Milan, Italy. LB declares the following competing interests, that are not directly related to any content in the supplement: Simpatica, Scientific Advisory Board Member, Jan. 2017 –present. Stemlmmune Scientific and Medical Advisory Board, April 2017-present. SapVax Advisory Board meeting, Philadelphia, PA, Nov 2017; Dec.2018. NextCure, Scientific Advisory Board, 2018-present. Replimmune, Scientific Advisory Board, 2018-present. Western Oncolytics, Scientific Advisory Board, 2018-present. Torque Therapeutics, Scientific Advisory Board, 2018-present. RD has intermittent, project focused consulting and/or advisory relationships with: Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, outside the submitted work. PA has received consulting fees from BMS, Roche, Gentech, MSD, Array, Amgen, Incyte, Pierre Fabre, Novertis, Genmab, Newlinks Genetics, Medimmune, Syndax, Sanofi, Idera, Sun Pharm, Ultimovacs, Sandoz, Immunos. Contracted research with: BMS, Roche, Array. Travel support with: MSD. CB declares no competing interests. GM Declares no competing interests.SD has received funding from: Lytix Biopharma - Advisory Board, Research grant. AbbVie Inc. – Consultant Honorarium. AstraZeneca AB – Consultant Honorarium. EMD Serono – Consultant Honorarium. Cytune Pharma Consultant Honorarium. Nanobiotix SA - Research grant. IP has served as a consultant for Amgen, Roche and Abbvie.

Naples, ItalyNovember 28 - December 1